The most common medical device in the world is also one of the most wasteful. Hundreds of millions of plastic, multi-dose inhalers are prescribed annually for conditions like asthma and COPD, creating a significant environmental footprint and a complex user experience for single-dose therapies. Edinburgh-based 1nhaler Ltd is betting that a radically simpler design, one that folds from a flat piece of cardboard into a three-dimensional inhaler, can address both problems at once [Archangels, 2024]. The company is not selling directly to patients, but positioning its proprietary dry-powder platform as a delivery vehicle for pharmaceutical partners, targeting a wide range of inhaled medicines from respiratory drugs to treatments for epilepsy and depression.
The bet on a flat, single-dose platform
At its core, 1nhaler's proposition is a manufacturing and patient experience wedge. The device is designed to be credit-card-sized and flat until a patient pops it into its 3D form for a single use [Archangels, 2024]. This format aims to solve several pain points simultaneously. For patients, it promises simplicity and portability, potentially improving adherence for short-course treatments like antibiotics or rescue medications. For pharmaceutical companies, a single-dose, propellant-free platform could simplify drug development and packaging logistics. The environmental claim is explicit: a cardboard device represents a low-carbon alternative to traditional plastic and aluminum inhalers, a point emphasized by the company's investors [Scottish Enterprise, 2024]. The technology hinges on a patent-protected membrane dispersion system designed to reliably aerosolize a variety of dry-powder medicines [Archangels, 2024].
A team built for the regulatory path
What makes 1nhaler's long-term bet credible is the pharmaceutical industry pedigree of its leadership, a critical asset for navigating the multi-year regulatory pathway to market. The company has systematically recruited veterans from the very giants that dominate the inhalable drug market.
| Role | Name | Key Prior Experience |
|---|---|---|
| Chief Scientific Officer | Helen Muirhead | Head of GSK's Respiratory Centre of Excellence; development lead for Diskus and Ellipta inhalers [Archangels, 2024] |
| Board Chair | Jane Gaddum | VP, Global Marketing for Emerging Brands at AstraZeneca [Archangels, 2024] |
| Non-Executive Director | Joanne Kelley | VP, Business Development at AstraZeneca [CB Insights] |
This team composition signals a deep understanding of the clinical development and commercial partnership playbooks necessary to bring a novel drug-delivery device to patients. Their presence provides a layer of validation that extends beyond the prototype, suggesting 1nhaler is structured to engage with big pharma on its own terms.
Funding a multi-year runway to market
1nhaler's financial backing reflects a regional support system and patience for a hardware-biotech hybrid. The company has raised approximately £3.5 million (around $4.4 million) across three seed rounds since 2023, all led by the Scottish investment syndicate Archangels [UK Tech News, Nov 2023][Finsmes, Nov 2025]. This capital is earmarked for advancing the device through development and toward a targeted Market Authorization Application (MAA) in Europe by late 2027, a timeline that implies a careful, phase-gated approach [Private candid take]. The consistent lead investor suggests confidence in the technical milestones, while partnerships with contract development and manufacturing organizations (CDMOs) like Upperton and Harro Höfliger point to early execution on the supply chain [HARRO, 2022].
The competitive and commercial landscape
No novel drug delivery platform exists in a vacuum, and 1nhaler's success hinges on convincing partners that its platform offers distinct advantages. The competitive set includes established players like MannKind Corporation, with its disposable inhaler technology, and companies like OptiNose and Impel NeuroPharma, which have pioneered novel delivery routes for neurology. The risks for 1nhaler are characteristic of the space:
- Technical equivalency. The device must demonstrate bioequivalence to existing delivery methods for each drug formulation, a costly and time-consuming process for every new application.
- Partner dependency. Without its own drug pipeline, 1nhaler's commercial future is tied to securing pharmaceutical development partners. No such public partnerships have been announced yet.
- Market timing. The push for sustainability in medical devices is growing, but payer and provider adoption often lags behind environmental intent, especially if cost premiums are involved.
The company's broad target list, spanning asthma, COPD, influenza, anaphylaxis, epilepsy, depression, and Parkinson's, is both a sign of ambition and a strategic necessity [Archangels, 2024]. It allows them to cast a wide net for partner interest, though the regulatory and development burden will differ drastically across those disease states.
For patients living with conditions like severe asthma or epilepsy, the standard of care today involves a mix of bulky plastic inhalers, pre-loaded syringes, or nasal sprays. These devices can be inconvenient to carry, intimidating to use correctly, and generate persistent plastic waste. A truly disposable, simple-to-use format could meaningfully change the experience for acute treatments, particularly in pre-hospital or community settings. The next twelve months for 1nhaler will likely focus on generating the preclinical data needed to secure that first pivotal pharmaceutical partnership, the true inflection point for a platform play built on cardboard and membrane technology.
Sources
- [Archangels, 2024] 1nhaler hires pharma industry leaders for key roles | https://www.scottish-enterprise-mediacentre.com/news/1nhaler-hires-pharma-industry-leaders-for-key-roles-ahead-of-clinical-trials
- [UK Tech News, Nov 2023] Scottish startup raises £2m for single-use inhaler | https://www.uktech.news/medtech/1nhaler-single-use-inhaler-20231127
- [Finsmes, Nov 2025] 1nhaler Raises £1.5M in Funding | https://www.finsmes.com/2025/11/1nhaler-raises-1-5m-in-funding.html
- [Scottish Enterprise, 2024] 1nhaler funding announcement | https://www.scottish-enterprise-mediacentre.com/news/1nhaler-hires-pharma-industry-leaders-for-key-roles-ahead-of-clinical-trials
- [CB Insights] 1nhaler company profile | https://www.crunchbase.com/organization/1inhaler
- [HARRO, 2022] 1nhaler - Passion and patience | https://www.harro-magazine.com/en/13-2022/1nhaler-passion-and-patience